eli lilly oral glp 1 Lilly's GLP-1 pill outperforms Novo's treatment in diabetes study A new class of oral

This study included 7,010 adults with diabetes treated with insulin and GLP-1s with over 300,000 treated with insulin and no GLP-1s

Abbreviations GLP1-RA: Glucagon like peptide-1 receptor agonist ASCVD: Atherosclerotic cardiovascular disease MACE: Major adverse cardiovascular events NNT: Numbers Needed to Treat MI: Myocardial Infarction CVD: Cardiovascular Disease SGLT2i: Sodium-glucose cotransporter-2 inhibitors LEADER: Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results T2DM: Type 2 Diabetes mellitus SELECT: Semaglutide effects on cardiovascular outcomes in people with overweight or obesity PREVENT: Predicting risk of cardiovascular disease events HF: Heart Failure PRISMA: Preferred reporting items for systematic review and meta-analyses RCT: Randomized controlled trial BMI: Body mass index RR: Risk ratio NNTB: Numbers needed to benefit NNTH: Number needed to harm ROB-2: Cochrane risk of bias 2 (ROB-2) tool FLOW: Evaluate renal function with semaglutide once weekly References Federation WH

Strategic fill-finish capacity was simultaneously secured through Novo Holdings' $16.5 billion acquisition of CDMO giant Catalent, through which Novo Nordisk gained three dedicated fill-finish manufacturing sites in Anagni, Italy, Brussels, Belgium, and Bloomington, Indiana, employing more than 3,000 people

doi:10.1523/JNEUROSCI.4770-06.2007

On MyPsoriasisTeam, more than 114,000 members come together to ask questions, give advice, and share their stories with others who understand life with psoriasis